Switching cholinesterase inhibitor therapy in Alzheimer's disease - donepezil to rivastigmine, is it worth it?

被引：34
|
作者：
Bullock, R [1 ]
Connolly, C [1 ]
机构：
[1] Victoria Hosp, Kingshill Res Ctr, Swindon SN1 4HZ, Wilts, England
来源：
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY | 2002年 / 17卷 / 03期
关键词：
D O I：
10.1002/gps.542
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
[No abstract available]
引用
收藏
页码：288 / 289
页数：2
相关论文
共 50 条
  • [31] Switching cholinesterase inhibitors in patients with Alzheimer's disease
    Emre, M
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, : 64 - 72
  • [32] Two cases of Alzheimer's disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil
    Kimura, Takemi
    Takamatsu, Junichi
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2013, 9 : 49 - 53
  • [33] The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease
    Loveman, E
    Green, C
    Kirby, J
    Takeda, A
    Picot, J
    Payne, E
    Clegg, A
    HEALTH TECHNOLOGY ASSESSMENT, 2006, 10 (01) : III - +
  • [34] Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease
    Blesa, Rafael
    Bullock, Roger
    He, Yunsheng
    Bergman, Howard
    Gambina, Giuseppe
    Meyer, Joanne
    Rapatz, Guenter
    Nagel, Jennifer
    Lane, Roger
    PHARMACOGENETICS AND GENOMICS, 2006, 16 (11): : 771 - 774
  • [35] Donepezil versus rivastigmine tolerability study in dementia with Lewy bodies and Alzheimer's disease
    Magierski, R.
    Sobow, T.
    Kloszewska, I.
    PARKINSONISM & RELATED DISORDERS, 2007, 13 : S62 - S62
  • [36] Persistence with Cholinesterase Inhibitor Treatment in Alzheimer's Disease
    Massoud, Fadi
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2013, 40 (05) : 623 - 624
  • [37] Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment
    Dantoine, T
    Auriacombe, S
    Sarazin, M
    Becker, H
    Pere, JJ
    Bourdeix, I
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (01) : 110 - 118
  • [38] Metabolic responses to donepezil therapy in Alzheimer's disease
    Mega, MS
    Cummings, JL
    Masterman, DM
    Dinov, ID
    Felix, J
    O'Connor, SM
    Toga, AW
    NEUROLOGY, 2000, 54 (07) : A416 - A416
  • [39] The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease
    Mega, MS
    Masterman, DM
    O'Connor, SM
    Barclay, TR
    Cummings, JL
    ARCHIVES OF NEUROLOGY, 1999, 56 (11) : 1388 - 1393
  • [40] Study of neuroprotection of donepezil, a therapy for Alzheimer's disease
    Akasofu, S.
    Kimura, M.
    Kosasa, I.
    Sawada, K.
    Ogura, H.
    CHEMICO-BIOLOGICAL INTERACTIONS, 2008, 175 (1-3) : 222 - 226
12345